Health Condition 1: J988- Other specified respiratory disorders
Conditions
Interventions
Intervention1: Vitamin D supplementation: Vit D at the weekly dose of 60000 IU will be given via oral administration (in form of tablets)
Control Intervention1: standard TB therapy as approved by WHO:
Sponsors
Department Of Health Research
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients belonging to both sex, i.e. male and females of 18 yrs and above age group 2. Patients willing to provide written informed consent 3. Patients diagnosed with TB (Sputum +, microbiologically diagnosed) 4. Patients with no other coronary heart disease and malignant tumors 5. Patients on first line therapy (sensitive patients)
Exclusion criteria
Exclusion criteria: 1. Patients with severe organ diseases or liver dysfunctions 2. Patients who are not willing to provide written informed consent 3. Patients with mental illnesses 4. Patients with history of allergy to the study drugs 5. Patients with human immuno deficiency virus, upper respiratory tract infection, any infectious disease conditions which is asymptomatic, Hepatitis B and C
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Since vitamin D possess antibacterial effect, therefore, it may reduces the inflammatory AGE-RAGE pathway and eventually, TNF-alpha in TB patientsTimepoint: The effect of supplementation will be observed in nearly 3 months or when patients will become sputum negative | — |
Secondary
| Measure | Time frame |
|---|---|
| Not applicableTimepoint: Not applicable | — |
Countries
India
Contacts
Public ContactDr Savita Devi
Kalpana Chawla Govt. Medical College, Karnal
Outcome results
None listed